Eagle Pharmaceuticals Reports First Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Dara Khosrowshahi steps down from Grab Holdings board
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 27c
May 11, 2020 6:52 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $0.84, $0.27 better than the analyst estimate of $0.57. Revenue for the quarter came in at $46 million versus the consensus estimate of $51.1 million.
2020 Expense Guidance
R&D spend in 2020, on a non-GAAP basis, is expected to... More